Total Funding
65
63
Total FundingGrant raised
Growth Score 65 in past quarter
-4 pts
Heat Score 63 in past quarter
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
186015
GangaGen is a clinical-stage biotechnology company focused on developing novel therapeutic proteins
- Janakiraman Ramachandran: Chairman & CEO
About the Company
GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. Using a proprietary platform, GangaGen is developing highly-specific therapeutic proteins called ectolysins to target clinically
meaningful types of bacteria. The company’s lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA).
